Thus, remarkable synergistic reduction was observed after this combination treatment, suggesting that stERAP-6 enhanced the responsiveness of anti-breast cancer drugs to ERα-positive breast cancer cells. The gene discussed is ESR1; the disease is breast carcinoma.